Roquette To Acquire IFF Pharma Solutions in Up to $2.85 Billion Deal

Roche to Acquire 89bio for Up to $3.5 Billion

September 22, 2025

Pharmaceuticals

Roche has reached an agreement to acquire 89bio, a biopharmaceutical company focused on treatments for liver diseases and cardiometabolic conditions. The deal is expected to close in the fourth quarter of 2025, with an offered price of $14.50 per share in cash plus potential contingent value rights tied to performance milestones for pegozafermin.

Roche Acquires Carmot Therapeutics for $2.7 Billion Upfront

December 4, 2023

Biotechnology

Carmot Therapeutics entered into a definitive merger agreement to be acquired by Roche for $2.7 billion upfront, with up to $400 million in potential milestone payments. Carmot’s shareholders will receive $2.7 billion in cash at closing, and Carmot and its employees will join the Roche Group’s Pharmaceuticals Division.

IFF Acquires Health Wright Products

February 16, 2022

Healthcare Services

IFF (International Flavors & Fragrances) entered into an agreement to acquire Health Wright Products, LLC, a dietary supplement formulation and capsule manufacturing provider. The deal is expected to close in the first quarter of 2022, subject to customary conditions and regulatory clearances, and financial terms were not disclosed.

Merck to Acquire Verona Pharma for Approximately $10 Billion

July 9, 2025

Pharmaceuticals

Merck, through a subsidiary, entered into a definitive agreement to acquire Verona Pharma in a transaction valued at approximately $10 billion (at $107 per ADS). The acquisition is intended to add Ohtuvayre (ensifentrine) to Merck’s cardio-pulmonary pipeline, following FDA approval for COPD in June 2024.

Faes Farma to Acquire SIFI to Build Leading Ophthalmology Franchise

June 10, 2025

Healthcare Services

SIFI shareholders have signed an agreement to sell 100% of SIFI shares to Faes Farma, a European pharmaceutical company listed on the Spanish stock exchange. The deal is expected to close in Q3 2025, subject to regulatory approvals and Faes Farma’s extraordinary shareholders’ meeting.

Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+

October 26, 2023

Healthcare Services

Roche entered into a definitive agreement to acquire Telavant Holdings, a company jointly owned by Roivant and Pfizer, for an upfront purchase price of $7.1 billion plus a near-term $150 million milestone payment. The deal gives Roche full rights to further develop, manufacture, and commercialize Telavant’s TL1A-directed antibody RVT-3101 in the US and Japan, with Pfizer retaining commercialization rights outside those territories.